Amerikanische Gesellschaft für Hirudotherapie

Delayed-onset, persisting autoimmune heparin-induced thrombocytopenia with thrombosis following craniofacial surgery

Case report published in BMJ Case Reports (2026)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportKlinische StudienArzneimittelentwicklungWill VJ et al. · BMJ Case Reports, 2026

Abstract

We report a case of a patient who developed delayed-onset, persisting autoimmune heparin-induced thrombocytopenia (HIT) following prophylactic anticoagulation with unfractionated heparin (UFH) after surgical treatment of a complex midfacial and mandibular fracture. Four days after stopping prophylactic anticoagulation, the patient developed pulmonary embolism and mild thrombocytopenia. HIT was initially not suspected and therapeutic anticoagulation was started. The patient subsequently developed severe thrombocytopenia consistent with HIT. Despite cessation of UFH and initiation of argatroban, thrombocytopenia did not improve. A HIT-antibody immunoassay and functional assay (HIPA) was strongly positive, and HIPA showed activity even in the absence of heparin, supporting the diagnosis of delayed-onset, persisting autoimmune HIT (aHIT). The patient was treated with immunoglobulin, resulting in a rapid recovery of platelet counts. This case highlights the importance of early recognition and appropriate management of aHIT, especially in patients with persisting thrombocytopenia despite standard HIT therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleCase Reports
Indexed MeSH termsHumansHeparinAnticoagulantsThrombocytopeniaPulmonary EmbolismMaleThrombosisPostoperative ComplicationsPurpura, Thrombocytopenic, IdiopathicFemaleMiddle Aged

Zusammenfassung

Delayed-onset autoimmune HIT (aHIT) following heparin prophylaxis after craniofacial fracture repair; HIPA assay was positive even without heparin, and only argatroban plus IVIG resulted in platelet count recovery.

Warum dies für die Hirudotherapie relevant ist

This case report describes a patient who developed delayed-onset, persisting autoimmune heparin-induced thrombocytopenia (aHIT) with thrombosis following prophylactic unfractionated heparin after surgical treatment of a complex midfacial and mandibular fracture, with pulmonary embolism and severe thrombocytopenia developing despite cessation of UFH and initiation of argatroban. A strongly positive HIPA assay showing activity even in the absence of heparin supported the aHIT diagnosis, and treatment with immunoglobulin resulted in rapid platelet recovery. The article has no direct relevance to ASH's domain: the abstract makes no mention of hirudin, lepirudin, leeches, or any leech-derived therapy. CAVEAT: This is a single case report focused on autoimmune HIT pathogenesis and immunomodulatory treatment; it contains no leech-related content, and any connection to hirudotherapy or the leech secretome is absent.

Zitation

Delayed-onset, persisting autoimmune heparin-induced thrombocytopenia with thrombosis following craniofacial surgery.

Will VJ et al. · BMJ Case Reports, 2026

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.